Therapeutic Antibodi - Re Directorate

RNS No 7476e
THERAPEUTIC ANTIBODIES INC
9th February 1998


                 THERAPEUTIC ANTIBODIES INC.
              ANNOUNCES APPOINTMENT OF NEW C.E.O

LONDON, FEBRUARY 9, 1998, - Therapeutic Antibodies Inc. (TAb)
announced today that Andrew Heath M.D., Ph.D. will join the
Company as Chief Executive Officer, effective March 1, 1998.

Dr. Heath will be elected to TAb's Board and will serve as Vice
Chairman of the corporation.  Martin S. Brown, the Company's
Chairman and Chief Executive Officer, will continue as Chairman
of the Board of Directors.

Mr. Brown said, "For some time the Company has planned to hire
a C.E.O.  with extensive pharmaceutical experience.  We are
extremely fortunate to gain Dr. Heath's services at this
critical point in TAb's development.  His unique background in
pharmaceutical industry management, along with his clinical
experience, provides a remarkable fit for our product
portfolio.  TAb will profit significantly from Dr. Heath's
expertise as these products progress through clinical trials
and reach the market place."

Dr. Heath, a native of England, holds a science degree in
pharmacology from the University of London and an M.D. from
Sweden's Gothenberg University.  He has considerable experience
in the pharmaceutical industry with Glaxo and Astra.  Until
1996, he was responsible for more than 500 sales and marketing
professionals for Astra U.S. as Vice President Marketing and
Sales.  In that post, he had profit and loss responsibility for
Astra USA's pharmaceutical portfolio.  He moves to TAb from the
position of C.E.O. at AeroGen Inc, a privately held drug
delivery company.

Therapeutic Antibodies Inc. is an international
biopharmaceutical company specialising in research, development
and production of highly purified polyclonal antibodies for
treatment of diseases and other life-threatening conditions for
which satisfactory therapies have generally not previously
existed.

CONTACTS:

Therapeutic Antibodies Inc              Martin Brown
001 615-327-1027                        A.J. Kazimi

Brunswick                               Stephen Breslin
0171 404-5959                           Frank De Maria


Notes to Editors:

The TAb Group

Therapeutic Antibodies Inc. is an international
biopharmaceutical group specialising in research, development
and production of highly  purified polyclonal antibodies for
treatment of diseases and other life-threatening conditions for
which satisfactory therapies have generally not previously
existed.

Established in 1984, TAb is headquarters in Nashville,
Tennessee, adjacent to the Vanderbilt University Medical
Center.  TAb has developed a series of emergency medicine
products, including antivenoms and drug antidotes to control
overdoses of digitalis products and tricyclics antidepressants.
TAb's products were developed at the Company's research
laboratories located at the Medical College of St.
Bartholomew's Hospital in London, U.K.  They are manufactured
at TAb's production facilities in Wales and Australia.
Therapeutic Antibodies is listed on the London Stock Exchange
(TAB.L).

Dr. Andrew Heath

Dr. Andrew Heath is board certified in anaesthesiology and
intensive care and holds a Ph.D. for a thesis in clinical
toxicology with primary focus on the toxicity of tricyclic
antidepressants.  His earlier background includes six years as
Director  of Intensive Care at Sahlgrens Hospital, University
of Gothenberg, and service as Associate Professor of Medicine
and Pediatrics and Director of the Poison Control Center and
Clinical Toxicology Unit at Vanderbilt University Medical
Center.  Following his academic career, Dr. Heath entered the
pharmaceutical industry joining Glaxo and subsequently Astra.

The author of more than 150 articles, Dr. Heath has served as
an officer on numerous international committees in the field of
toxicology.

TAb's Major Products

CytoTAbTM  is an anti-cytokine product that has been proven to
neutralise the important cytokine tumour necrosis factor (TNF).
Elevated concentrations of TNF have been identified in a
growing number of life-threatening or disabling conditions,
making TNF a primary therapeutic target for treatment.  TAb is
presently engaged in clinical studies evaluating the efficacy
of CytoTAbTM in the treatment of cerebral malaria, human
sepsis, organ transplant rejection, the Jarisch-Herxheimer
Reaction and Acute Graft vs. Host Disease.

CroTAb(registered) is an antivenom product which preclinical
studies have shown to be five times more potent from current
therapies in offsetting the poisonous effect of North American
pit vipers (rattlesnakes, copperheads and cottonmouths).
Clinical trials have indicated a promising safety profile for
CroTAb(registered), a major clinical consideration given that
existing antivenoms have a high incidence of serious side-
effects.  Phase III studies have been satisfactorily completed
and TAb is preparing to submit applications for regulatory
approval for CroTAb(registered).

DigiTAbTM has been developed to negate the effects of digoxin
poisoning, frequently seen among congestive heart failure
patients.  This product is currently in Phase III clinical
evaluation in the United States and Europe.

TriTAbTM is being developed to reverse the toxicity stemming
from overdose of tricyclic antidepressants, a leading cause of
life-threatening poisoning episodes seen in emergency medicine.
Up to 60,000 patients per year might benefit from an effective
treatment.  Currently, there is no antidote for overdose of
this widely-used family of products.  A dose finding clinical
study is being readied.

An  electronic version of this news release is available on the
Company's home page at http://www.tab.co.uk


END

BOAAILVAFFIAIAT